INTELLIA THERAPEUTICS, INC. Cost of Revenue
INTELLIA THERAPEUTICS, INC. (NTLA) reported Cost of Revenue of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2022-02-24
- INTELLIA THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2019-12-31 was $0.00.
- INTELLIA THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2019-09-30 was $0.00.
- INTELLIA THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2019-06-30 was $0.00.
- INTELLIA THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2019-03-31 was $0.00.
- INTELLIA THERAPEUTICS, INC. cost of goods and services sold for fiscal 2021 was $0.00.
- INTELLIA THERAPEUTICS, INC. cost of goods and services sold for fiscal 2020 was $0.00.
- INTELLIA THERAPEUTICS, INC. cost of goods and services sold for fiscal 2019 was $0.00.
- INTELLIA THERAPEUTICS, INC. cost of goods and services sold for fiscal 2018 was $0.00.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-24 | |||
| 2020-12-31 | $0.00 10-K · filed 2021-02-26 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | $0.00 10-K · filed 2020-02-27 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $0.00 derived: sum of 2 quarters · filed 2019-10-31 | $0.00 10-Q · filed 2019-10-31 | $0.00 derived: sum of 4 quarters · filed 2019-10-31 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $0.00 10-Q · filed 2019-08-01 | $0.00 derived: sum of 3 quarters · filed 2019-08-01 | $0.00 derived: sum of 4 quarters · filed 2019-08-01 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-02 | $0.00 derived: sum of 2 quarters · filed 2019-05-02 | $0.00 derived: sum of 3 quarters · filed 2019-05-02 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $0.00 derived: sum of 2 quarters · filed 2019-02-27 | $0.00 10-K · filed 2019-02-27 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $0.00 10-Q · filed 2018-10-31 | ||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |